Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 5
2016 8
2017 3
2018 13
2019 24
2020 15
2021 20
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Delany-Moretlwe S, et al. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Lancet. 2022. PMID: 35378077 Free PMC article. Clinical Trial.
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, Jean-Philippe P, Johnston B, Krotje C, Fairlie L, Hoffman RM, Sax PE, Moyo S, Chakhtoura N, Stringer JS, Masheto G, Korutaro V, Cassim H, Mmbaga BT, João E, Hanley S, Purdue L, Holmes LB, Momper JD, Shapiro RL, Thoofer NK, Rooney JF, Frenkel LM, Amico KR, Chinula L, Currier J; IMPAACT 2010/VESTED Study Team and Investigators. Lockman S, et al. Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7. Lancet. 2021. PMID: 33812487 Free PMC article. Clinical Trial.
What is new in perinatal HIV prevention?
Fowler MG, Flynn P, Aizire J. Fowler MG, et al. Curr Opin Pediatr. 2018 Feb;30(1):144-151. doi: 10.1097/MOP.0000000000000579. Curr Opin Pediatr. 2018. PMID: 29315112 Free PMC article. Review.
Efavirenz pharmacokinetics during pregnancy and infant washout.
Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D. Kreitchmann R, et al. Antivir Ther. 2019;24(2):95-103. doi: 10.3851/IMP3283. Antivir Ther. 2019. PMID: 30530925 Free PMC article.
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Chinula L, Ziemba L, Brummel S, McCarthy K, Coletti A, Krotje C, Johnston B, Knowles K, Moyo S, Stranix-Chibanda L, Hoffman R, Sax PE, Stringer J, Chakhtoura N, Jean-Philippe P, Korutaro V, Cassim H, Fairlie L, Masheto G, Boyce C, Frenkel LM, Amico KR, Purdue L, Shapiro R, Mmbaga BT, Patel F, van Wyk J, Rooney JF, Currier JS, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Chinula L, et al. Lancet HIV. 2023 Jun;10(6):e363-e374. doi: 10.1016/S2352-3018(23)00061-9. Epub 2023 May 8. Lancet HIV. 2023. PMID: 37167996 Clinical Trial.
Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial.
Shah SK, London AJ, Mofenson L, Lavery JV, John-Stewart G, Flynn P, Theron G, Bangdiwala SI, Moodley D, Chinula L, Fairlie L, Sekoto T, Kakhu TJ, Violari A, Dadabhai S, McCarthy K, Fowler MG. Shah SK, et al. Clin Trials. 2021 Dec;18(6):681-689. doi: 10.1177/17407745211045734. Epub 2021 Sep 15. Clin Trials. 2021. PMID: 34524048 Free PMC article. Review.
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial.
Cherkos AS, LaCourse SM, Enquobahrie DA, Richardson BA, Bradford S, Montepiedra G, Mmbaga BT, Mbengeranwa T, Masheto G, Jean-Phillippe P, Chakhtoura N, Theron G, Weinberg A, Cassim H, Raesi MS, Jean E, Wabwire D, Nematadzira T, Stranix-Chibanda L, Hesseling AC, Aurpibul L, Gupta A, John-Stewart G; IMPAACT P1078 TB APPRISE Study Team. Cherkos AS, et al. EClinicalMedicine. 2023 Mar 17;58:101912. doi: 10.1016/j.eclinm.2023.101912. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 36969345 Free PMC article.
Neurodevelopmental outcomes of HIV/antiretroviral drug perinatally exposed uninfected children aged 3-6 years.
Fowler MG, Hanrahan C, Yende N, Stranix-Chibanda L, Chipato T, Maliwichi L, Gadama L, Aizire J, Dadabhai S, Chinula L, Wambuzi-Owang L, Owor M, Violari A, Nyati M, Hanley S, Govender V, Brummel S, Taha T. Fowler MG, et al. AIDS. 2022 Sep 1;36(11):1533-1543. doi: 10.1097/QAD.0000000000003290. Epub 2022 Jun 22. AIDS. 2022. PMID: 35730383 Free PMC article.
Predictors of Viremia in Postpartum Women on Antiretroviral Therapy.
Hoffman RM, Warshaw MG, Amico KR, Pilotto J, Masheto G, Achalapong J, Machado E, Chokephaibulkit K, Duarte G, João E, Graham KK, Knapp KM, Stek AM, Scott GB, Coletti A, Loftis AJ, Chakhtoura N, Currier JS; PROMISE 1077HS Team. Hoffman RM, et al. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):72-80. doi: 10.1097/QAI.0000000000002228. J Acquir Immune Defic Syndr. 2020. PMID: 31651545 Free PMC article. Clinical Trial.
98 results